The Success Story of LDL Cholesterol Lowering

Circulation Research

Volumn 118, Issue 4, 2016, Pages 721-731

  Pedersen, Terje R ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

atherosclerosis; cholesterol, LDL; coronary artery disease; primary prevention; secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CLOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; BLOOD ANALYSIS; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DIET SUPPLEMENTATION; DRUG SCREENING; ESTROGEN THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LOW FAT DIET; MEDICAL HISTORY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; NONHUMAN; PHARMACOLOGICAL SCIENCE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WORLD HEALTH ORGANIZATION; ANIMAL; BLOOD; CORONARY ARTERY DISEASE; HISTORY; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DIET, FAT-RESTRICTED; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84959056614     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306297     Document Type: Article

References (108)

1. Vogel J., The Pathological Anatomy of the Human Body 1847 London H. Baillere
2. Anitschkow N., Über die veränderungen der kaninchenaorta bei experimenteller Cholesterinsteatose. Beitr Pathol Anat Allgem Pathol 1913 56 379 404
3. Bailey CH., Atheroma and other lesions produced in rabbits by cholesterol feeding. J Exp Med 1916 23 69 84
4. Bacmeister A, Henes E., Untersuchungen über den Cholesteringehalt des menschlichen Blutes bei verschiedenen inneren Erkrankungen. Deuts Med Wochenschr 1913 39 544 546
5. Dock W., Atherosclerosis. Why do we pretend the pathogenesis is mysterious? Circulation 1974 50 647 649
6. Leary T., Atherosclerosis, the important form of arteriosclerosis, a metabolic disease. JAMA 1935 105 475 481
7. Dock W., The predilection of atherosclerosis for the coronary arteries. JAMA 1946 131 11 875 878. doi: 10.1001/jama.1946.02870280001001.
8. Morrison LM., Reduction of mortality rate in coronary atherosclerosis by a low cholesterol-low fat diet. Am Heart J 1951 42 538 545
9. Leren P., The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. Acta Med Scand Suppl 1966 466 1 92
10. Leren P., The Oslo diet-heart study. Eleven-year report. Circulation 1970 42 935 942
11. Miettinen M, Turpeinen O, Karvonen MJ, Elosuo R, Paavilainen E., Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet 1972 2 835 838
12. Mann GV., Diet-Heart: end of an era. N Engl J Med 1977 297 644 650. doi: 10.1056/NEJM197709222971206.
13. Ederer F, Leren P, Turpeinen O, Frantz ID Jr., Cancer among men on cholesterol-lowering diets: Experience from five clinical trials. Lancet 1971 2 203 206
14. Oliver MF, Boyd GS., Influence of reduction of serum lipids on prognosis of coronary heart-disease. A five-year study using oestrogen. Lancet 1961 2 499 505
15. Marmorston J, Moore FJ, Hopkins CE, Kuzma OT, Weiner J., Clinical studies of long-term estrogen therapy in men with mvocardial infarction. Proc Soc Exp Biol Med 1962 110 400 408
16. Stamler J, Pick R, Katz LN, Pick A, Kaplan BM, Berkson DM, Century D., Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA 1963 183 632 638
17. Oliver MF, Boyd GS., Reductuon of serum-cholesterol by dextro-thyroxine in men with coronary heart-disease. Lancet 1961 1 783 786
18. Oliver MF., Reduction of serum-lipid and uric-acid levels by an orally active androsterone. Lancet 1962 1 1321 1323
19. The Coronary Drug Project Research Group The Coronary Drug Project. Design, Methods, and Baseline Results. Circulation 1973 47 suppl 1 I-1 I-50
20. The Coronary Drug Project Research Group The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA 1970 214 1303 1313
21. The Coronary Drug Project Research Group The Coronary Drug Project.Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 1972 220 996 1008
22. The Coronary Drug Project Research Group The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA 1973 226 652 657
23. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease. JAMA 1975 231 360 381
24. Trial of clofibrate in the treatment of ischemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne Region. Br Med J 1971 4 767 775
25. Ishcemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. Br Med J 1971 4 775 784
26. Dewar HA, Oliver MF., Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Br Med J 1971 4 784 786
27. Heady JA., A cooperative trial on the primary prevention of ischaemic heart disease using clofibrate: design, methods, and progress. Bull World Health Organ 1973 48 243 256
28. Committee of Principal Investigators A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Br Med J 1978 40 1069 1118
29. Oliver MF., Serum cholesterol-the knave of hearts and the joker. Lancet 1981 2 1090 1095
30. Oliver MF., Prevention of coronary heart disease-propaganda, promises, problems, and prospects. Circulation 1986 73 1 9
31. Oliver MF., Dietary fat and coronary heart disease. Br Heart J 1987 58 423 428
32. Oliver MF., Reducing cholesterol does not reduce mortality. J Am Coll Cardiol 1988 12 814 817
33. The Lipid Research Clinics Program The coronary primary prevention trial: design and implementation. J Chron Dis 1979 32 609 631
34. Tennent DM, Siegel H, Zanetti ME, Kuron GW, Ott WH, Wolf FJ., Plasma cholesterol lowering action of bile acid binding polymers in experimental animals. J Lipid Res 1960 1 469 473
35. Levy RI, Fredrickson DS, Stone NJ, Bilheimer DW, Brown WV, Glueck CJ, Gotto AM, Herbert PN, Kwiterovich PO, Langer T, LaRosa J, Lux SE, Rider AK, Shulman RS, Sloan HR., Cholestyramine in type II hyperlipoproteinemia. A double-blind trial. Ann Intern Med 1973 79 51 58
36. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984 251 351 364
37. Buchwald H, Stoller DK, Campos CT, Matts JP, Varco RL., Partial ileal bypass for hypercholesterolemia. 20-to 26-year follow-up of the first 57 consecutive cases. Ann Surg 1990 212 318 329; discussion 329
38. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr., Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990 323 946 955. doi: 10.1056/NEJM199010043231404.
39. Rodney G, Uhlendorf P, Maxwell RE., The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals. Proc R Soc Med 1976 69 suppl 2 6 10
40. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V., Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987 317 1237 1245. doi: 10.1056/NEJM198711123172001.
41. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P., Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988 260 641 651
42. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 341 410 418. doi: 10.1056/NEJM199908053410604.
43. Concensus Conference Lowering blood cholesterol to prevent heart disease. JAMA 1985 253 2080 2086
44. Steinberg D., The cholesterol controversy is over. Why did it take so long? Circulation 1989 80 1070 1078
45. Muldoon MF, Manuck SB, Matthews KA., Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990 301 309 314
46. Strandberg TE, Salomaa VV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA., Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991 266 1225 1229
47. Oliver MF., Doubts about preventing coronary heart disease. BMJ 1992 304 393 394
48. Siperstein MD, Guest MJ., Studies on the site of the feedback control of cholesterol synthesis. J Clin Invest 1960 39 642 652. doi: 10.1172/JCI104079.
49. Endo A., The origin of the statins. 2004. Atheroscler Suppl 2004 5 125 130. doi: 10.1016/j.atherosclerosissup.2004.08.033.
50. Endo A, Kuroda M., Citrinin, an inhibitor of cholesterol synthesis. J Antibiot (Tokyo) 1976 29 841 843
51. Endo A, Kuroda M, Tanzawa K., Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976 72 323 326
52. Brown AG, Smale T, King TJ, Hasenkamp R, Thompson RH., Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevcompactum. J Chem Soc Perkin 1976 I 1165 1170
53. Endo A., The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl 2004 5 67 80. doi: 10.1016/j.atherosclerosissup.2004.08.026.
54. Yamamoto A, Sudo H, Endo A., Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980 35 259 266
55. Endo A., Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979 32 852 854
56. Alberts AW, Chen J, Kuron G, Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980 77 3957 3961
57. Illingworth DR, Sexton GJ., Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 1984 74 1972 1978. doi: 10.1172/JCI111618.
58. Goldstein JL, Brown MS., Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974 249 5153 5162
59. Brown MS, Goldstein JL., Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA 1974 71 788 792
60. Kovanen PT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS., Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 1981 78 1194 1198
61. Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS., Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986 83 8370 8374
62. Norman DJ, Illingworth DR, Munson J, Hosenpud J., Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988 318 46 47. doi: 10.1056/NEJM198801073180110.
63. East C, Alivizatos PA, Grundy SM, Jones PJ, Farmer JA., Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988 318 46 47
64. Tobert JA., Response to ref, 59-60. N Engl J Med 1988 318 48
65. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP., Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991 151 43 49
66. Staffa JA, Chang J, Green L., Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002 346 539 540. doi: 10.1056/NEJM200202143460720.
67. Hamm CW., European perspective. Circulation 2009 120 f115 f120
68. The Scandinavian Simvastatin Survival Study Group Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 1993 71 393 400
69. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 1383 1389
70. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 1301 1307. doi: 10.1056/NEJM199511163332001.
71. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 335 1001 1009. doi: 10.1056/NEJM199610033351401.
72. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyörälä Miettinen T, Wilhelmsen L, Olsson AG, Wedel H., Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995 345 1274 1275
73. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ., Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998 97 1453 1460
74. West of Scotland Coronary Prevention Study Group Influence of pravastatin and plasma lipids on clinical events in th West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998 97 1440 1445
75. Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E., Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998 97 1446 1452
76. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 1349 1357
77. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A, LIPID Study Investigators Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002 105 1162 1169
78. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 1495 1504. doi: 10.1056/NEJMoa040583.
79. de Lemos JA, Blazing MA, Wiviott SD, Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004 292 1307 1316. doi: 10.1001/jama.292.11.1307.
80. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 1425 1435. doi: 10.1056/NEJMoa050461.
81. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005 294 2437 2445. doi: 10.1001/jama.294.19.2437.
82. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Study Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind trial. Lancet 2010 376 1658 1669
83. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010 376 1670 1681
84. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279 1615 1622
85. The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997 336 153 162
86. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico) Results of the low dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction; do stopped trials contribute to overall knowledge? Ital heart J 2000 1 810 820
87. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001 285 1711 1718
88. Heart Protection Study Collaborative Group MRC/BHF Geart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk uindividuals: a randomized placebo-controlled trial. Lancet 2002 360 7 22
89. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B, Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 287 3215 3222
90. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG., Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002 18 220 228
91. Shepherd J, Blauw GJ, Murphy MB, PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 360 1623 1630
92. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholestrolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002 288 2998 3007
93. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 361 1149 1158. doi: 10.1016/S0140-6736(03)12948-0.
94. Holdaas H, Fellström B, Jardine AG, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003 361 2024 2031. doi: 10.1016/S0140-6736(03)13638-0.
95. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 685 696. doi: 10.1016/S0140-6736(04)16895-5.
96. Koren MJ, Hunninghake DB, ALLIANCE Investigators Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004 44 1772 1779. doi: 10.1016/j.jacc.2004.07.053.
97. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 353 238 248. doi: 10.1056/NEJMoa043545.
98. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006 368 1155 1163. doi: 10.1016/S0140-6736(06)69472-5.
99. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High dose atorvastatin after stroke of transient ischemic attack. N Engl J Med 2006 355 549 559
100. Kjekshus J, Apetrei E, Barrios V, CORONA Group Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 357 2248 2261. doi: 10.1056/NEJMoa0706201.
101. GISSI-HF Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008 372 1231 1239
102. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, for the JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2088 359 21995 2207
103. Fellström BC, Jardine AG, Schmieder RE, AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009 360 1395 1407. doi: 10.1056/NEJMoa0810177.
104. Baigent C, Landray MJ, Reith C, SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011 377 2181 2192. doi: 10.1016/S0140-6736(11)60739-3.
105. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015 385 1397 1405
106. Cannon CP, Blazing MA, Giugliano RP, IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 372 2387 2397. doi: 10.1056/NEJMoa1410489.
107. Robinson JG, Farnier M, Krempf M, ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1489 1499. doi: 10.1056/NEJMoa1501031.
108. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1500 1509. doi: 10.1056/NEJMoa1500858.